As filed with the Securities and Exchange Commission on September 12, 2001
Registration No. 333-62770
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
----------------
PRE-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
----------------
CARESIDE, INC.
(Exact name of registrant as specified in its charter)
Delaware 3841 23-2863507
(State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer
incorporation or organization) Classification Code Number) Identification No.)
6100 Bristol Parkway, Culver City, CA 90230
(310) 338-6767
(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)
----------------
W. Vickery Stoughton
Chairman of the Board of Directors and
Chief Executive Officer
Careside, Inc.
6100 Bristol Parkway
Culver City, CA 90230
(310) 338-6767
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
----------------
With copies to:
Barry M. Abelson, Esq.
Julia D. Corelli, Esq.
Pepper Hamilton LLP
3000 Two Logan Square
Philadelphia, PA 19103
(215) 981-4000
----------------
Approximate date of commencement of proposed sale to the public: As soon as
practicable after this Registration Statement becomes effective.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [_]
If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or
interest reinvestment plans, check the following box. [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [_]
If this Form is a post-effective amendment filed pursuant to Rule 462(C)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [_]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
check the following box. [_]
----------------
CALCULATION OF REGISTRATION FEE
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Proposed Proposed
Maximum Maximum Amount of
Title of Each Class of Amount to be Offering Price Aggregate Registration
Securities to be Registered Registered Per Share Offering Price Fee
-------------------------------------------------------------------------------------
Common Stock, par value
$.01....................... 14,195,890 (2) (2) (2)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
(1) All of the shares of Common Stock offered hereby are being sold for the
accounts of selling stockholders named herein. See "Selling Stockholders"
herein. We initially included 14,482,743 shares of common stock on this
registration statement when we filed it on June 11, 2001. We are removing
286,853 shares, leaving a balance of 14,195,890 shares of common stock
registered herein.
(2) A registration fee of $8,043.96 was previously paid in connection with the
initial filing of this registration statement on June 11, 2001 based on a
proposed maximun offering price per share of $2.415 and a proposed maximum
aggregate offering price of $34,975,824.35, calculated at that time in
accordance with Rule 457(c) under the Securities Act.
----------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT
SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THIS REGISTRATION STATEMENT
SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION,
ACTING PURSUANT TO SECTION 8(A), MAY DETERMINE.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
14,195,890 Shares Of Common Stock
[LOGO OF CARESIDE]
The selling stockholders named in this prospectus are offering or may offer
in the future 14,195,890 shares of our common stock which we have issued or
which we may issue when selling stockholders exercise warrants to purchase our
common stock.
The selling stockholders may sell these shares from time to time in brokers'
transactions, negotiated transactions, or otherwise at prices current at the
time of sales. We will not receive any proceeds from these sales.
We will pay all expenses of the registration of these shares, except
brokerage commissions and transfer taxes, which will be paid by the selling
stockholders. We estimate that the expenses will be $50,000.
Our common stock is listed on the American Stock Exchange under the symbol
"CSA." On September 10, 2001, the closing sale price of our common stock as
reported by the American Stock Exchange was $2.58 per share.
Investing in our common stock involves significant risks. See "Risk Factors"
beginning on page 4.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if
this prospectus is truthful or complete. Any representation to the contrary is
a criminal offense.
September 12, 2001
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
----------------
TABLE OF CONTENTS
. About Careside ........................ 1
. The Offering........................... 3
. Risk Factors........................... 4
. Special Note Regarding Forward-Looking
Statements............................. 14
. Use of Proceeds........................ 14
. Dilution............................... 15
. Selling Security Holders............... 16
. Careside's Capital Structure........... 21
. Plan of Distribution................... 22
. Legal Matters.......................... 24
. Experts................................ 25
. Where You Can Get More Information..... 26
. Incorporation of Certain Documents by
Reference.............................. 26
----------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
ABOUT CARESIDE
This summary does not contain all of the information that you should consider
before investing in our common stock. You should read the entire prospectus
carefully, including the "Risk Factors" section, the financial statements and
the notes to those financial statements.
Careside
Careside has developed and sells a proprietary blood testing system called
the Careside system. It is designed to decentralize laboratory operations. The
system consists of two blood testing devices and disposable cartridges and
reagents used in the devices as well as a computer link. The Careside
Analyzer(R) tests each of the three components of blood--whole blood, serum and
plasma. It uses our proprietary disposable test cartridges and performs 41
different tests. The H-2000 performs 18 hematology tests on whole blood. The
Careside Connect facilitates data interchange between the two devices and other
medical information systems.
The Careside system performs blood tests in the same location as the patient,
or what is commonly called point-of-care testing. Blood testing is a
significant part of routine and critical patient care. Today, almost all blood
testing is done by sending the blood samples to hospital or commercial
laboratories. Because of transportation time and several processing steps,
these central laboratories generally take between 4 and 24 hours to provide
test results to the doctor. We believe that the Careside system is a platform
for solving the limitations of central blood testing laboratories and redefines
the market for point-of-care testing.
Our goal is to make decentralized testing with the Careside system the
standard for routine and critical care blood testing.
As of August 2001, the FDA has cleared or exempted the Careside Analyzer for
all 41 blood tests for professional laboratory use and the H-2000 for 18
additional hematology tests. The Careside system's 59 different blood tests
represent most of the routine blood tests ordered by physicians. In addition,
the FDA has cleared the Careside Analyzer as a "point-of-care" device. This
clearance means that properly trained non-technical personnel can operate the
Careside Analyzer, eliminating the need for a lab specialist to oversee each
test. We intend to seek the same designation for the H-2000 in 2001.
Our commercial product launch occurred in December 1999, at which time the
Careside system offered 53 tests. By the beginning of the second quarter of
2000, we were experiencing issues in both the software and hardware of the
Careside Analyzer that made us question the reliability of the device in the
field. We also experienced technical problems with electrochemistry tests. As a
result, we pulled back from the market and corrected the issues that gave rise
to the reliability concerns. We did not lose any customers or have to
repurchase any devices or have to seek any additional governmental approvals as
a result of these technical difficulties. Rather, we worked with our customers
to ensure the reliability of the test results each customer received from the
Analyzer. We completed the revisions to the electrochemistry tests and
modifications to the Analyzer by November 2000. The revisions were made and
verified in the fourth quarter of 2000. The changes delayed our ability to
market the Analyzer and its disposable cartridges. As a result, our sales
through early 2001 were predominantly H-2000s.
At present, we sell the components of the Careside system separately in the
United States through our own sales force. We have distribution agreements with
third party distributors to supplement our sales force. We have entered into
several distribution agreements and expect to finalize others in 2001. To date,
our H-2000 sales have been weighted towards foreign markets and veterinary use.
We are focusing our 2001 marketing efforts on the U.S. human market.
Our concept and technology originated with SmithKline Beecham Clinical
Laboratories, Inc. (SBCL). In 1993, SBCL conducted extensive surveys of the
point-of-care market. As a result, in 1994, SBCL started our predecessor
business to develop the technology we use today. In November 1996, we acquired
the assets and
contracts used in the predecessor business, including intellectual property,
equipment and other assets to continue the development of point-of-care
diagnostic technology and to create a commercial product. Several senior
members of our management team worked on this point-of-care project at SBCL,
including W. Vickery Stoughton, our Chief Executive Officer, and Thomas H.
Grove, Executive Vice President--Chief Technology Officer. Quest Diagnostics
Incorporated later acquired SBCL.
Our publicly-traded common stock is listed on the American Stock Exchange
under the ticker symbol "CSA," and our publicly-traded warrants under the
symbol "CSA.WS". Our principal executive offices are located at 6100 Bristol
Parkway, Culver City, California 90230. Our telephone number is (310) 338-6767.
2
THE OFFERING
Shares offered by selling
security holders:.......... 14,195,890 (1)
Use of Proceeds:............ We will not receive any of the proceeds from the sale of
shares of common stock by the selling stockholders, but we
could receive up to approximately $14.4 million from the
exercise of warrants with underlying common stock registered
on this registration statement (see "Dilution" on page 14).
Any proceeds will be used for working capital purposes (2).
--------
(1) Of these shares, approximately
. 8,417,655 are shares of common stock held by the selling stockholders,
of these,
. 6,475,451 shares of common stock were issued upon conversion of
outstanding shares of our series C convertible preferred stock on the
day prior to effectiveness of this registration statement at an
assumed conversion price of $1.55 per share. The actual conversion
price will be 80% of the average trading price of our common stock
over the five trading days prior to effectiveness of the registration
statement of which this prospectus is a part. The actual conversion
price will not be less than $1.55 or more than $1.94,
. 199,253 shares of common stock were issued upon conversion of shares
of our series B preferred stock and were not previously registered,
and
. 1,742,951 shares were issued in a private placement to a single
investor in December 2000 and January 2001.
. 41,324 shares of common stock are issuable upon exercise of warrants
exercisable at $2.75 per share,
. 45,824 shares of common stock are issuable upon exercise of warrants
exercisable at $2.25 per share,
. 5,173,716 shares of common stock are issuable upon exercise of
outstanding warrants issued in connection with the sale of our Series C
Convertible Preferred Stock at an exercise price of $2.55 per share, and
. 517,371 shares of common stock are issuable upon exercise of outstanding
warrants issued to our placement agent in connection with the sale of
our Series C Convertible Preferred Stock at an exercise price of $1.94
per share.
(2) This figure assumes that those warrants are exercised without using their
cashless exercise feature.
3
RISK FACTORS
An investment in our common stock involves many risks. These risks may be
substantial and are inherent in the business of Careside. You should carefully
consider the following information about these risks, together with the other
information in this prospectus, before buying common stock.
If any of the following risks actually occurs, our business and prospects
could be materially adversely affected, the trading price of our common stock
or warrants could decline, and you might lose all or part of your investment.
We Have A Limited Operating History By Which To Evaluate Our Business
We have no history which would demonstrate an ability to generate revenue.
Since our inception, we have incurred significant losses. Through December 31,
2000 and June 30, 2001 our accumulated losses have totaled $45.2 million and
$52.2 million, respectively. We have generated only a small amount of revenue
from product sales and will continue to incur significant additional operating
losses until we have sold a sufficient number of our products. Because we have
a limited operating history, we have not demonstrated an ability to:
. respond to competitive developments;
. develop new relationships and maintain existing relationships with
suppliers, distributors and potential customers;
. attract, retain and motivate qualified employees; and
. produce, distribute and market our product.
We May Never Be Profitable
Even if we are able to generate revenue from sales of our products, we may
never be profitable. There are several reasons why this might happen:
. We may not be able to reduce our manufacturing costs to levels necessary
for profitability.
. We may have to lower our prices to remain competitive.
. We may experience delays in developing additional tests or product
upgrades.
. We may experience problems in production, distribution or marketing.
Even if we are able to generate revenue from sales of our products, we may
never be profitable. There are several reasons why this might happen:
. We may not be able to reduce our manufacturing costs to levels necessary
for profitability.
. We may have to lower our prices to remain competitive.
. We may experience delays in developing additional tests or product
upgrades.
. We may experience problems in production, distribution or marketing.
Even if we do achieve profitability, we may not sustain or increase
profitability on a quarterly or annual basis in the future.
4
Given Our Limited Operating History And Recurring Losses, We May Be Unable To
Continue As A Going Concern
Since our inception, we have generated minimal revenues, incurred significant
losses from operations and accumulated some debt. We anticipate that we will
incur additional losses over at least the next year. Our consolidated financial
statements for each of the three years in the period ended December 31, 2000
have been prepared assuming that we will continue as a going concern. As
indicated in our consolidated financial statements for the year ended December
31, 2000, we incurred a net loss in 2000 of $16,703,485 and used cash for
operating activities of $15,661,957. Our accumulated deficit was $45,199,361.
Careside's independent accountants have stated in their audit opinion that
these factors raise substantial doubt about Careside's ability to continue as a
going concern. Further, additional financing will be needed by Careside to fund
its operations. If we were to seek additional debt or equity financing in the
future, these factors, including the going-concern language in our independent
accountant's audit opinion, might hinder our ability to do so. In the event our
operations are not profitable or do not generate sufficient cash to fund our
business, there will be substantial doubt about our ability to continue as a
going concern.
Unavailability Of Additional Funding May Adversely Affect Our Business
At June 30, 2001, our principal source of liquidity was approximately $5.6
million in cash and cash equivalents. Our current liquidity and sales revenue
expected in 2001 are projected to be sufficient to fund our operating expenses
and capital requirements for at least eight months. Our future liquidity and
capital funding requirements will depend on numerous factors, including:
. the extent to which our products gain market acceptance;
. the exercise of outstanding warrants to purchase common stock;
. the timing of regulatory actions regarding our products; and
. the costs and timing of expansions of sales, marketing and manufacturing
activities.
Additional capital may not be available on terms acceptable to us, if it is
available at all. If adequate funds are not available, our business, results of
operations and financial condition could be materially and adversely affected.
We may be required to delay, reduce or eliminate product development programs.
We may also have to reduce our planned marketing and sales activities, or
license to third parties rights to commercialize our products or technologies.
These reductions could, in turn, affect our relationships with our clients and
threaten our ability to continue as a going concern.
The Medical Community May Not Accept the Careside System
The Careside Analyzer and our patented test cartridges, the H-2000 and the
Careside Connect are our only products. We will not be able to operate
profitably unless these products achieve a significant level of market
acceptance. The following factors are the greatest risks to our market
acceptance:
We May Fail to Develop the Comprehensive Test Menu Needed to Sell Our Product
If we are not able to fully develop further tests to complete our proposed
comprehensive test menu, customers may not buy our products. One of our major
selling points to potential customers will be the breadth of our menu.
We May Be Unable to Change How Tests Are Ordered
We may not be able to demonstrate the economic or clinical benefits of the
Careside system sufficiently to convince members of the medical community to
change the way they order tests. Currently, physicians and hospitals typically
order blood tests from central laboratories.
5
Managed Care Contracts May Limit Our Market Penetration
Our ability to sell to healthcare providers may be limited by managed care
relationships. Many health maintenance and managed care organizations have
exclusive contracts with laboratories that require participating or employed
physicians to send patient specimens only to contracted laboratories.
Consequently, these physicians may be precluded from using Careside's products
unless they obtain a waiver from the relevant health maintenance or managed
care organization.
We May Be Unable To Keep Pace With Changing Technology
Blood testing technology is evolving. Other companies may develop products in
response to technological changes that make our products noncompetitive.
CLIA May Discourage Healthcare Providers From Using Point-of-Care Testing
Careside system users will have to be licensed under the Clinical Laboratory
Improvement Amendments of 1988. While the Careside system is designed to make
licensure easy, CLIA licensing requirements may make healthcare providers
reluctant to initiate, continue or expand patient testing using the Careside
system.
We May Not Be Able To Further Develop Our Products
In order for us to expand our test menu, we must complete the development of
one of the four types of disposable cartridges. The immunochemistry cartridge
has been designed but has not undergone testing. Factors outside our control
may delay our proposed development schedule for this cartridge. These factors
include:
. delays in regulatory clearance,
. technological difficulties,
. restrictions on access to proprietary technology of strategic partners,
and
. changes in the healthcare, regulatory or reimbursement environment.
Reductions In Third-Party Reimbursement For Tests May Hurt Our Business
We believe that decreases in third-party reimbursement amounts for diagnostic
tests may reduce the demand for diagnostic tests performed by our products at
the point of care. Government authorities, private health insurers and other
third-party payers, such as health maintenance organizations, have the power to
determine reimbursement amounts paid to test providers for diagnostic tests.
Historically, they have decreased these reimbursement amounts more often than
they have increased them. While we have no knowledge of any upcoming decreases,
the potential for them exists. Providers would earn less revenue from testing
if reimbursement rates decrease. Because it may not be profitable enough in
light of reimbursement rates, providers could choose to cease or not to start
conducting point-of-care testing. This could, in turn, decrease the demand for
our products or force us to lower our sales prices. This could lower our
revenues.
Our Limited Sales, Marketing and Distribution Experience May Hurt Our Sales
We may not be able to recruit or retain direct sales and marketing personnel
who will successfully implement our marketing strategy. We intend to distribute
our products in the United States through our own sales force and domestic
distributors, and internationally through distributors. Establishing a sales
and marketing capability will require substantial efforts and significant
resources.
6
Ineffectiveness Of Third-Party Distributors May Hurt Our Sales
We will depend on third party distributors to assist us in promoting market
acceptance and creating demand for our products. We have granted Fuji Photo
Film Co. Ltd. a right of first refusal to distribute the Careside system
exclusively in Japan and non-exclusively in some of the other Asian countries.
Our existing arrangements to distribute our products worldwide may not be
sufficient. We may not be able to maintain these arrangements or enter into
additional distribution arrangements. In addition, we have little control over
the resources that distributors will devote to the marketing of our products.
Our Contract Manufacturers May Not Adequately Meet Our Future Product Demand
We will depend upon outside vendors to manufacture most of the Careside
system, including the Careside Analyzer and components of the disposable
testing cartridges. We have only limited control over third-party manufacturers
as to quality control and timing of production and delivery. We cannot be
certain that outside manufacturers will be able to provide us with a sufficient
number of instruments and cartridge components on a timely basis.
At present, we depend on UMM Electronics, Inc. for the manufacture and supply
of Analyzers and Fuji Photo Film Co., Ltd. for dry film used in our cartridges.
Each of those suppliers has contracted to supply to us all of the products we
order from them. If we do not negotiate extensions, our contract with UMM will
expire in the first quarter of 2004 and our contract with Fuji will expire on
December 31, 2003. There are alternative suppliers to UMM and Fuji. However, if
we are required to switch manufacturers or suppliers on short notice, the
manufacture of our products could be delayed and the supply of our products
could be interrupted. This could reduce our revenues.
Our Inability To Forecast Our Dry Film Requirements Could Result In Excess Film
Inventory
Our contract with Fuji requires us to forecast our requirements for dry film
on a periodic basis. If we do not accurately forecast our needs, we may end up
with too much or too little supply of dry film. Excess film inventory could
result in obsolescence since dry film has a limited shelf life. Too little
inventory could hurt our ability to meet our customers' orders.
Our Lack Of Manufacturing Experience Could Prevent Us From Meeting Cartridge
Demand
We will be assembling the cartridges at Careside. We have limited experience
operating a manufacturing/assembly business. We will need to assemble
significant and increasing quantities of test cartridges on a timely basis,
while maintaining strict quality standards. We have converted from manual
production of cartridge components and assembly to an automated system to
produce cartridge components. We may not be able to achieve and maintain
product accuracy and reliability when producing the cartridges in the
quantities required, on a timely basis or at an acceptable cost.
Loss Of Our CEO Or Other Key Personnel Would Hinder The Success Of Our Business
The loss of key employees or unsuccessful recruiting efforts will harm us.
Competition for qualified and talented individuals with experience in point-of-
care testing is intense. Our success depends on our ability to retain the
services of Mr. Stoughton, our Chairman of the Board of Directors and Chief
Executive Officer. Mr. Stoughton has over 20 years experience as a senior
executive of several large hospitals and over four years experience as
President of SmithKline Beecham Clinical Laboratories, Inc. We also need to
attract additional sales and marketing, research and development, and
experienced manufacturing personnel.
Failure To Manage The Expansion Of Our Operations May Hurt Our Business
We will need to expand our operations if we are successful in achieving
market acceptance for the Careside system. This expansion will result in
additional responsibilities for management and place significant
7
demand upon our management, our operating and financial systems and our
resources. To accommodate this growth and to compete effectively, we will need
to implement and improve our internal operating systems and controls, and to
hire and train additional personnel. Failure to do so may impede our success.
Our Competitors Have Advantages Over Us
Our business may fail because our market is highly competitive. Our primary
competitors are large diagnostic device manufacturers, commercial and hospital
laboratories and other point-of-care device manufacturers. The large device
manufacturers and commercial and hospital laboratories have significant
marketing, manufacturing, financial and managerial resources, and have
substantially greater research and development capabilities than we do. We
expect that manufacturers of conventional blood testing products used in
centralized laboratories will compete intensely with us to maintain their
market share. Commercial and hospital laboratories may try to influence
providers against the Careside system to protect their revenue. Other point-of-
care companies have already sold their product in the marketplace. We
anticipate competition from these manufacturers in discrete testing areas such
as critical care testing. Many of these companies offer tests that will cost
less than the Careside system and so may be attractive to some of our
customers.
Failure To Protect Our Proprietary Technology Is A Crucial Part of Our Business
The success of our business will depend on our ability to protect our
proprietary technology. Our business may fail if we are not able to do so.
We currently have three U.S. patents granted on our cartridge technology. Six
other patents have been filed to date and we expect to file additional patents
in the future. International patents have also been filed. The six patents
filed to date include one that was filed jointly with International Technidyne
Inc. and covers a reagent that was co-discovered. The other five include one
more cartridge patent and four device patents. We cannot be certain that these
additional patents will be granted or that our patents will withstand any
challenges by third parties. Factors impacting our proprietary technology,
which may ultimately impact our success, include:
Our Technology May Infringe on the Proprietary Rights of Third Parties
Universities and government laboratories, physicians and other corporations
are conducting substantial research in point-of-care diagnostic blood testing
technology. Given the nature of our industry, it is possible that patent
applications have been filed by others, and patents may be issued to them,
relating to specific diagnostic products and processes. Patent applications in
the U.S. are secret until the patent is issued. We cannot know whether
competing applications have been filed. A prior conflicting patent application
would detract from the value of our patents. In addition, if we use
technologies, products or processes covered by patent applications filed by
others, or by patents issued to others, we may have to obtain licenses. We may
not be able to obtain such licenses on reasonable terms, or at all.
We May Be Unable to Build Brand Loyalty Because Our Trademarks and Trade Names
May Not Be Protected
Our registered or unregistered trademarks or trade names may be challenged,
canceled, infringed, circumvented or declared generic or determined to be
infringing on other marks. We may not be able to protect our rights to these
trademarks and trade names, which we need to build brand loyalty. Brand
recognition is critical to our short term and long term marketing strategies.
Our Trade Secrets May Be Disclosed
We also rely on unpatented trade secrets to protect our proprietary
technology. We attempt to protect our proprietary technology through an
employee handbook and agreements with our executive officers. Our
8
employees have not signed confidentiality agreements. The confidentiality
provisions in the handbook and executives' agreements may not be enforceable
under applicable law. Other companies may independently develop or otherwise
acquire equivalent technology or gain access to our proprietary technology.
Our Proprietary Rights May Fail to Protect Our Business
We may have to resort to litigation to protect or defend our rights. This
could result in substantial costs and the diversion of management's attention.
If we lost any such litigation, we could lose our competitive position, be
required to obtain licenses from third parties or be prevented from
manufacturing, selling or using certain of our products.
We Do Not Own All Necessary Intellectual Property
The film in all of our test cartridges and the electrochemistry slide in our
electrochemistry test cartridge is manufactured by and is based on patents
owned by Fuji Photo Film Co., Ltd. Fuji may terminate its contract with us upon
one year's notice if it discontinues manufacturing and marketing this film. It
also may terminate the contract if we become bankrupt or insolvent or if we
transfer significant assets to a third party, if there is a material change in
control of us, or if we breach the agreement and the breach is not cured within
thirty days. If our access to these Fuji products terminated, we would have to
use other products that would be based on alternative technology. We would not
be able to utilize Fuji's patents to manufacture our own film and
electrochemistry slide because we do not have a perpetual license to Fuji's
patents if Fuji terminates its contract with us. We believe that such other
products do exist, but we cannot be sure that we would be able to achieve
access to any such technology on a timely basis. Conversion to the alternative
technology could not start until we achieved access to the alternative
technology. If we have to use products based on alternative technology, we may
have to modify our product to accommodate this new technology. This could cause
substantial delay and cost. If alternative technology is unavailable, we would
have to change our testing methodologies. This could also cause substantial
delay and cost. We presently have no indication that our access to the Fuji
products is threatened and we believe that there is only a small risk that we
would be denied access to alternative technologies.
Extensive Government Regulation May Increase Our Expenses and Cause Delays In
Our Product Commercialization
Our products are medical devices subject to extensive regulation by the FDA,
similar agencies in other countries, and to a lesser extent, by state
regulatory authorities. The following are the greatest regulatory risks we
face:
We May Incur Substantial Expenses to Comply With Good Manufacturing Practices
(GMP) and Other Manufacturing Regulations
Our manufacturing facilities and processes will be required to comply with
strict federal regulations, including Good Manufacturing Practices, or GMP, and
quality system requirements, regarding validation and quality of manufacturing.
We have limited experience in complying with regulations governing our products
and manufacturing facilities. We must devote substantial resources and
management attention to monitoring and maintaining compliance with governmental
regulations. If we, or our manufacturing partners, violate applicable
regulations, we may be sanctioned and our production or distribution may be
suspended. In addition, the FDA may withdraw the approval or clearance to
market of any of our products.
We May Need to Apply For Additional FDA Pre-Market Clearances if We
Significantly Modify Our Products or Add to Our Test Menu, Which May Result In
Rejections Or Delays
We are continuously subject to FDA regulations regarding laboratory and
clinical testing. When we seek to improve our product and add additional tests
to our test menu, we may be required to submit new applications for pre-market
clearance. We cannot be certain that we will be able to obtain all necessary
approvals for product improvements or additional tests on a timely basis, or at
all. Such delays or rejections could adversely affect our business.
9
The Issuance Of Significant Number Of Shares That Are Eligible For Future Sale
Could Lower Our Market Price
We have a significant amount of common stock that could enter the public
market in the future. The public resale of these shares could have a depressive
effect on the market price of our common stock.
The following are the shares that may be issued in the future:
. 2,000,000 common shares issuable upon exercise of our outstanding public
warrants will become available for resale in the public market upon
issuance;
. 1,461,779 common shares issuable upon exercise of our outstanding
options or options that we may grant in the future under our current
stock option plans, or pursuant to our employee stock purchase plan,
will become available for resale in the public market upon issuance;and
. 11,471,788 common shares issuable upon exercise of outstanding warrants
that are not publicly traded will become available for resale in the
public market upon issuance
A Large Percentage Increase In Our Publicly Traded Common Stock May Lower The
Market Price of Our Common Stock
Since our initial public offering on June 16, 1999, we have issued common
stock and committed to issue common stock through warrants and options which we
have issued and through our Series A preferred stock which we may become
obligated to issue in the future. On a fully diluted basis, we have increased
our outstanding common stock since our initial public offering by 174%.
In this prospectus, we have registered the resale of 8,417,665 of our total
outstanding shares of common stock, which represents an increase of 46.3% in
the number of our publicly tradable shares. Also, we have outstanding options
and warrants that are exercisable into approximately a total of 14,484,273
shares of common stock, some of which are registered in this registration
statement and some of which have been previously registered. The issuance of
these shares would result in a 79.7% increase in our outstanding common stock.
The large percentage increases in our outstanding and registered common stock
could have a depressive effect on the market price of our common stock.
Holders Of Our Common Stock May Be Materially Diluted By The Exercise Of
Outstanding Warrants Issued In Connection With Our Series B And Series C
Preferred Stock
3,993,970 additional shares of our common stock may be issued upon the
exercise of the callable common warrant issued in 2000 to the purchaser of our
series B preferred stock. The exercise price of this warrant can be 95% of a
two day average market price of our common stock. Issuance of these warrant
shares at such price may have a depressive effect on the market price of our
common stock.
5,691,087 shares of our common stock may be issued upon the exercise of
warrants issued in 2001 in connection with the sale of our series C preferred
stock. The exercise price of these warrants is $2.55 for 5,173,716 of these
shares and $1.94 for the remaining 517,371 shares. If these shares are issued
at an exercise price that is less than the market price of our common stock at
that time, the holders of our common stock may be materially diluted.
The Conversion Of Our Series C Preferred Caused Dilution To Our Stockholders
Our series C preferred stock automatically converted on the day prior to the
effective date of this registration statement. The conversion price was 80% of
the five day average trading price prior to conversion, or $ . The 20% discount
from market may have a depressive effect on the market price of our common.
10
Control Of Careside By Our Management And Principal Stockholders Could Conflict
With Other Stockholders' Interests
The interests of our directors and executive officers, and our principal
stockholders could conflict with the interests of other Careside stockholders.
As of the date of this prospectus, our directors and executive officers,
together with the principal stockholders of Careside, beneficially own or
control approximately 46.7% of our common stock. This percentage takes into
account the effect of options and warrants. Accordingly, these stockholders may
be able to influence the outcome of stockholder votes, including votes
concerning the election of directors, certain amendments to our charter and
bylaws, and the approval of significant corporate transactions such as a merger
or a sale of our assets. This influence could have the effect of delaying,
deferring or preventing a change in control of Careside.
Future Issuances Of Preferred Stock May Dilute Rights Of Common Stockholders
Because of our liquidity needs, we have issued in the past three different
series of preferred stock. Each such series of preferred stock has had superior
rights to our common stock. The conversion of each series of preferred stock
into our common stock may have caused or may in the future cause dilution to
our stockholders. Currently, no shares of preferred stock are outstanding. We
are obligated to issue shares of series A preferred stock if the remaining $2
million of our bridge financing with S.R. One, Ltd. originally entered into in
December 1998 is converted. Given our liquidity position, we may have to seek
additional capital in the future as we have done in the past. Our Board of
Directors has the authority to issue up to 4,836,117 additional shares of
preferred stock in the future and to determine the price, privileges and other
terms of such shares. The Board may exercise this authority without the
approval of the stockholders. The rights of the holders of common stock may be
adversely affected by the rights of the holders of any preferred stock that may
be issued in the future. Specifically, our series A preferred stock is
preferred over common stock in dividends and has a liquidation preference over
common stock. In addition, the issuance of preferred stock may make it more
difficult for a third party to acquire control of Careside.
Delaware Law Charter And Our By-laws May Delay Or Prevent Someone From
Acquiring Us
We will be subject to the anti-takeover provisions of Section 203 of the
Delaware General Corporation Law. Section 203 could delay or prevent a third
party or a significant stockholder from acquiring control of us. In general,
Section 203 prohibits a publicly held Delaware corporation from engaging in a
business combination with an interested stockholder for a period of three years
following the date the person became an interested stockholder, unless the
business combination or the transaction in which the person became an
interested stockholder is approved in a prescribed manner. Generally, a
business combination includes a merger, asset or stock sale, or other
transaction resulting in a financial benefit to the interested stockholder. An
interested stockholder is a person who, together with affiliates and
associates, owns 15% or more of a corporation's voting stock. Section 203 may
prohibit or delay mergers or other takeover or change in control attempts with
respect to us. As a result, Section 203 may discourage attempts to acquire us
even though such transaction may offer our stockholders the opportunity to sell
their stock at a price above the prevailing market price.
In addition, our charter and by-laws contain anti-takeover protections that
may have the effect of lowering the market price of our stock because they may
discourage, delay or prevent a merger, tender offer or proxy contest involving
us. Specifically, our charter and bylaws contain the following anti-takeover
protections:
. the fact that we have a board of directors that is divided into three
classes of directors may have the effect of deterring or delaying any
attempt by any group to obtain control of us by a proxy contest. A
stockholder would be required to have its nominees elected at two
separate annual meetings in order to elect a majority of the members of
the board of directors;
11
. we may issue up to 4,836,117 shares of preferred stock that has whatever
rights, privileges and preferences our Board of Directors determines.
The issuance of preferred stock could be utilized as a method of
discouraging, delaying or preventing a change in control of our stock;
. our charter requires that stockholder action be taken at meetings and
not by written consent and that special meetings of stockholders may
only be called by a majority of our board of directors, our chairman or
our chief executive officer;
. our charter provides that directors can be removes from the Board only
for cause and only with the affirmative vote of holders of 80% or more
of our outstanding voting shares
. our charter requires a holders of 75%, and in some cases 80%, of our
outstanding shares to approve any amendment to our charter;
. stockholders must follow the advance notice procedures set forth in our
bylaws to nominate a person for director or submit proposals to our
Board of Directors; and
. our Board of Directors has broad discretion under our bylaws to
determine the number of directors that will constitute our Board and to
fill vacancies on the Board, including those created by increasing the
number of directors.
The Market Prices Of Shares Of Common Stock And Warrants May Be Volatile
The market prices of shares of common stock and warrants may be highly
volatile. This means our stock prices may fluctuate significantly depending on
many factors, including:
. the success of our new products or new products introduced by our
competitors,
. developments with respect to our patents and other proprietary rights,
. our ability to meet sales and earnings expectations of securities
analysts
. our need to raise financing through sale of our equity, and
. changes in general market conditions.
12
Our Total Assets Include Significant Intangible Assets And The Write-Off Of A
Significant Portion Of Unamortized Intangible Assets Would Negatively Affect
Our Results Of Operations
Our total assets reflect significant intangible assets. As of June 30, 2001,
we had approximately $1.9 million of net intangible assets representing 12.6%
of our total assets and 21.2% of our stockholders' equity. Intangible assets
consist of goodwill associated with our acquisition of Texas Instrument
Laboratories, Inc., representing the excess of the purchase price and related
costs over the value assigned to the tangible assets we acquired in that
acquisition. Periodically, we assess whether there has been an impairment in
the value of our goodwill. Beginning January 1, 2002, we will account for our
intangible assets under Statement of Financial Accounting Standards No. 142,
Goodwill and Other Intangible Assets. Under this standard, we will no longer
amortize our goodwill, but we will continue to periodically assess it for
impairment by comparing the carrying value to the estimated fair value. If the
estimated fair value is less than the carrying value, the goodwill will be
considered impaired and the impairment losses will be reported as an operating
expense in current results of operations. Any determination requiring the
write-off of a significant portion of unamortized intangible assets would
negatively affect our results of operations and total capitalization. As of
June 30 2001, we have determined that no impairment existed.
The Terms Of Some Of Our Securities May Encourage Short-Selling Of Our Common
Stock Which Could Depress The Market Price Of Our Common Stock
Until the warrants issued in 2001 in connection with our series B convertible
preferred stock are exercised, there may be increased risk of short-selling of
our common stock, which could have a depressive effect on the market price of
our common stock. The holder of this warrant can exercise on its own initiative
at $14 per share. Or, we can call this warrant in which case the exercise price
is 95% of the two day average trading price prior to the call. If we call the
warrant, then, by short-selling our common stock, the warrant holder could
depress the market price of our common stock, enabling the holder to acquire
shares upon any subsequent call of these warrants at a lower price.
A short-sale is the sale of a security that the seller does not own or that
the seller owns but does not deliver. In order to deliver the security to the
purchaser, the short-seller will borrow the security, typically from a broker-
dealer or an institutional investor. The short-seller later closes out the
position by returning the security to the lender, typically by purchasing
equivalent securities on the open market. In general, short-selling is utilized
to profit from an expected downward price movement, or to hedge the risk of a
long position in the same security or in a related security. Although short-
selling serves useful market purposes, it also may be used as a tool for
manipulation. Further, short-selling can increase stock price volatility.
Our series C convertible preferred stock converted automatically upon
effectiveness of this registration statement at a price that depended upon the
market price of our common stock. The lower the market price for our common
stock, the greater the number of shares of common stock the selling
stockholders could have acquired upon conversion of our series C convertible
preferred stock. Selling stockholders could have used a short-selling strategy
to drive down the market price of our common stock prior to the conversion.
This would increase the number of shares issued upon the conversion. Such a
short-selling strategy, if used, could have a depressive effect on the market
price of our common stock that has not yet been fully realized.
13
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements contained in this prospectus discuss future events and
developments, including our ability to generate revenue, income and cash flows,
or state other "forward-looking" information. We generally identify these
forward-looking statements by using the words "anticipate," "believe,"
"estimate," "expect," and similar expressions. These statements include, but
are not limited to, information about our cash available to fund our future
operations, future enhancements to our products, growth of the in vitro testing
and point-of-care testing markets, completion of the immunochemistry tests
cartridge, and the planned addition of further tests to our menu. Those
statements are subject to known and unknown risks, uncertainties and other
factors that could cause the actual results to differ materially from those
contemplated by the statements. Important factors that may cause actual results
to differ include those set forth under "Risk Factors" beginning on page 5.
We do not promise to update forward-looking information to reflect actual
results or changes in assumptions or other factors that could affect those
statements.
USE OF PROCEEDS
We will not receive any of the proceeds from the sale of the shares by the
selling stockholders pursuant to this prospectus. However, we may receive up to
approximately $14.4 million from the exercise of warrants with underlying
common stock registered hereunder. This figure assumes that those warrants are
exercised without using their cashless exercise feature. There is no guarantee
that any warrants will be exercised or that we will receive any proceeds. The
proceeds, if any, would be used for working capital purposes.
14
DILUTION
The selling security holders listed in this prospectus may offer and sell
shares of our common stock for their own account. We will not receive any
proceeds from any such sales.
Our net tangible book value as of June 30, 2001 was approximately $7,217,889,
or $0.63 per share of common stock. As the shares of common stock being
registered in this prospectus had already been issued in a private transaction,
there is no additional dilution to the net tangible book value per share of
common stock as a result of sales of shares registered in this registration
statement.
15
SELLING SECURITY HOLDERS
The following table sets forth certain information regarding the beneficial
ownership of the common stock as of August 31, 2001 by each of the selling
security holders. Unless otherwise indicated below, to our knowledge, all
persons listed below have sole voting and investment power with respect to the
shares of common stock, except to the extent authority is shared by spouses
under applicable law.
The information included below is based upon information provided by the
selling security holders and by our transfer agent. Because the selling
security holders may offer all, some or none of their common stock, no
definitive estimate as to the number of shares thereof that will be held by the
selling security holders after such offering can be provided. In the following
table, column (A) shows all shares beneficially held by the holder at August
31, 2001, and column (B) has been prepared on the assumption that all shares of
common stock registered under this Prospectus will be sold.
(B)
Common Stock To
Be Beneficially
(A) Owned If All
Common Stock Shares Registered
Beneficially Owned Prior Hereunder Are
to August 31, 2001 Sold
------------------------------- -----------------
Shares Shares That
Underlying May Be
Name Shares(1) Warrants Percent(2) Offered Hereunder Shares Percent(2)
---- --------- ---------- ---------- ----------------- ------ ----------
Abood, Thomas J.(3)..... 0 78,440 * 78,440 0 *
Abrahams, Louise H.(4).. 32,258 25,774 * 58,032 0 *
Abrahams, Richard
L.(5).................. 58,065 46,393 * 104,458 0 *
Abrahams, Richard L. &
Louise L., Trustees for
the Richard and
Louise Abrahams
Charitable Trust....... 16,129 12,887 * 29,016 0 *
Allison, Robert G. ..... 48,387 38,660 * 87,047 0 *
Anderson, Leonard....... 16,129 12,887 * 29,016 0 *
Anderson, Mary C. ...... 38,800 31,000 * 69,800 0 *
Asphalt Green, Inc.(6).. 33,003 21,000 * 47,283 6,720 *
Bear Stearns as
Custodian for Bruce
Hendry, IRA............ 322,580 257,732 3.1% 580,312 0 *
Bear Stearns as
Custodian for Demetre
M. Nicoloff, IRA....... 16,129 12,887 * 29,016 0 *
Bear Stearns as
Custodian for Jerry A.
Kuny, IRA.............. 16,129 12,877 * 29,016 0 *
Bear Stearns as
Custodian for Michael
D. Lensing............. 16,129 12,887 * 29,016 0 *
Bear Stearns as
Custodian for Steven D.
McWhirter, IRA(7)...... 16,129 12,887 * 29,016 0 *
Benenson, Paul A. ...... 16,129 12,887 * 29,016 0 *
Bergren, Gary A. ....... 19,354 15,464 * 34,818 0 *
Bigley, Robert.......... 16,129 12,887 * 29,016 0 *
Brattain, Donald R. .... 64,516 51,546 * 116,062 0 *
Campbell, Craig L. ..... 19,354 15,464 * 34,818 0 *
Castle Creek Health Care
Partners LLC(8)........ 483,870 386,598 4.7% 870,468 0 *
CCL Fund, LLC(9)........ 161,290 128,866 1.6% 290,156 0 *
16
(B)
Common Stock To Be
(A) Beneficially Owned
Common Stock If All Shares
Beneficially Owned Prior Registered
to August 31, 2001 Hereunder Are Sold
-------------------------------------- ------------------
Shares Shares That
Underlying May Be
Name Shares(1) Warrants Percent(2) Offered Hereunder Shares Percent(2)
---- --------- ---------- ---------- ----------------- ------- ----------
Cheney, Steven.......... 48,387 38,660 * 87,047 0 *
City of Stamford
Firemen's Pension
Fund(6)................ 95,654 46,000 * 103,574 38,080 *
Crestview Capital Fund,
LP(10)................. 322,603 257,750 3.1% 580,353 0 *
Dean Witter
Foundation(6).......... 90,843 52,000 117,083
Digges, Sasha L. and
Mary Catherine Knott
Digges................. 64,516 51,546 * 116,062 0 *
Dolan, Michael T.(3).... 0 1,804 * 1,804
Dolphin Offshore
Partners L.P.(11)...... 321,919 206,186 2.9% 464,250 63,855 *
Dougherty & Company
LLC(12)................ 274,193 219,072 2.7% 493,265 0 *
Dougherty, Michael
E.(3).................. 0 78,441 * 78,441 0 *
DRL Partners(13)........ 16,129 12,887 * 29,016 0 *
Elsholtz, Robert W. .... 16,129 12,887 * 29,016 0 *
Felling, Anthony(3)..... 0 19,407 * 19,407 0 *
Frantz, William T. ..... 225,145 128,866 1.9% 290,156 63,855 *
Friedli, Peter(14)
(15)................... 2,116,472(16) 130,122(17) 12.3% 1,830,099 416,495 2.3%
Frommelt, Jeffrey J. ... 24,193 19,330 * 43,523 0 *
Frommelt, Roger H. ..... 8,064 6,443 * 14,507 0 *
Gonyea, Dennis A. ...... 19,354 15,464 * 34,818 0 *
Hajas, Peter............ 451,612 360,825 4.4% 812,437 0 *
Harstad, Glen........... 16,129 12,887 * 29,016 0 *
Heidecker, Stephen C. .. 16,129 12,887 * 29,016 0 *
Hoel, Dorothy J. ....... 19,354 15,464 * 34,818 0 *
Horick, Jessica S.(18).. 0 7,895 7,895
Horick, Jonathan P.(3).. 0 93,000 * 93,000 0 *
Hunt, Helen............. 42,554 34,000 * 76,554 0 *
Johnson, Raymond R. .... 19,354 15,464 * 34,818 0 *
Kelly, Eugene V. ....... 6,945 51,546 * 116,062 22,429
Kessler Family Ltd.
Partnership(19)........ 161,290 128,866 1.6% 290,156 0 *
Kessler, Irvin R. ...... 483,870 386,598 4.7% 870,468 0 *
King, Russell S.(3)..... 0 7,000 * 7,000 0 *
Knopick, Alexander...... 0 5,291 * 5,291 0 *
Knott, William H. ...... 36,774 29,381 * 66,155 0 *
Kohler, Gary............ 64,516 51,546 * 116,062 0 *
Kozberg, Mark(3)........ 0 9,278 * 9,278 0 *
Kraut, Gerald(7)........ 0 78,441 * 78,441 0 *
L & Co., LLC(20)........ 64,516 51,546 * 116,062 0 *
Laube, James and
Judith................. 16,129 12,887 * 29,016 0 *
Lentz, Richard D. ...... 16,129 12,887 * 29,016 0 *
Lindberg, Aaron A.(3)... 0 5,000 * 5,000
17
(B)
Common Stock To Be
(A) Beneficially Owned
Common Stock If All Shares
Beneficially Owned Prior Registered Hereunder
to August 31, 2001 Are Sold
------------------------------- --------------------
Shares Shares That
Underlying May Be
Name Shares(1) Warrants Percent(2) Offered Hereunder Shares Percent(2)
---- --------- ---------- ---------- ----------------- --------- ----------
Lineberger, James E. ... 218,305 103,093 1.7% 232,125 89,273 *
Lloyd, Maria C. ........ 80,645 64,433 * 145,078 0 *
Marshman, Edward N.,
trustee u/a dtd 9/15/88
FBO Edward N. Marshman
Trust.................. 52,258 25,773 * 58,031 0 *
Marshman, Homer H.,
Jr. ................... 16,129 12,887 * 29,016 0 *
Mason, Stuart H.(3)..... 16,129 37,887 * 54,016 0 *
McWhirter, Steven D.(7)
(21)................... 32,258 120,511 * 123,753 0 *
Meehan Foundation(6).... 28,781 23,000 * 51,781 0 *
Milroy, Callista F., as
TTEE under the Trust
Agreement dated
10/15/99 for Callista
Milroy................. 18,129 12,887 * 29,016 2,000 *
Mitchell, Timothy(3).... 0 7,353 * 7,353 0 *
Nicoloff,
Demetre, M.(22)........ 32,258 25,774 * 58,032 0 *
OTATO Limited
Partnership(23)........ 129,032 103,093 1.3% 232,125 0 *
Paine Webber as
Custodian FBO Demetre
M. Nicoloff, IRA....... 16,129 12,887 * 29,016 0 *
Paymar, Robert H.(3).... 0 887 * 887
Perkins, Daniel S. and
Patrice M., JT WROS.... 50,064 40,000 * 90,064 0 *
Peterson, Mark(3)....... 2,500 902 * 902 2,500 *
Pint, Michael........... 32,258 25,773 * 58,031 0 *
Pint, Steve............. 32,258 25,773 * 58,031 0 *
Potter, James(3)........ 0 838 * 838 0 *
Potter, John T. ........ 16,129 12,887 * 29,016 0 *
Potter, Susan Noel(18).. 0 837 837
Public Employee
Retirement System of
Idaho(6) (14).......... 675,824 412,000 5.8% 927,664 160,160 *
Redleaf, Andrew J. ..... 64,516 51,546 * 116,062 0 *
RLA 1993 Trust(13)...... 41,936 33,506 * 75,442 0 *
Roycap, Inc. (14) (24).. 788,616 4,018,970 21.7% 199,253 4,608,333 25.3*
Sexton, William D. ..... 64,516 51,546 * 116,062 0 *
Shapiro, Lawrence B. ... 32,258 25,773 * 58,031 0 *
Snyder, Hans(3)......... 2,000 902 * 902 2,000 *
Spinner, G. James(3).... 21,129 14,305 * 30,434 5,000 *
Stovern, Lori........... 32,258 25,773 * 58,031 0 *
18
(B)
Common Stock To
Be Beneficially
(A) Owned If All
Common Stock Shares Registered
Beneficially Owned Prior Hereunder Are
to August 31, 2001 Sold
------------------------------- -----------------
Shares Shares That
Underlying May Be
Name Shares(1) Warrants Percent(2) Offered Hereunder Shares Percent(2)
---- --------- ---------- ---------- ----------------- ------ ----------
Strickland, Scott E. and
Mary T., JTWROS........ 16,129 12,887 * 29,016 0 *
The Peregrine Equity
Fund, LLP(25).......... 32,258 25,773 * 58,031 0 *
Theeuwes Family Trust,
Felix Theeuwes
Trustee................ 32,541 26,000 * 58,541 0 *
Thomssen, Robert........ 62,580 50,000 * 112,580 0 *
UBS--Piper Jaffray as
Custodian FBO
James G. Peters, IRA... 25,032 20,000 * 45,032 0 *
UBS Piper Jaffray as
Custodian FBO Bradley
A. Erickson, IRA....... 19,354 15,464 * 34,818 0 *
UBS Piper Jaffray as
Custodian FBO David H.
Potter, IRA............ 31,290 25,000 * 56,290 0 *
UBS Piper Jaffray as
Custodian FBO Richard
C. Perkins, IRA........ 41,935 33,505 * 75,440 0 *
Weinand, Shawn P........ 19,354 15,464 * 34,818 0 *
Westrum, David M........ 32,258 25,773 * 58,031 0 *
Williams, Bradley
D.(3).................. 0 500 * 500
Wilmington Trust
Company, Trustee u/a
dtd 1/21/27 with Philip
F. duPont for Jane
duPont Lunger(14)...... 516,129 412,371 5.0% 928,500 0 *
Wolfson Investment
Partners LP(6)......... 66,403 52,000 * 117,083 1,320 *
Zesiger, Barrie Ramsay.. 65,083 52,000 * 117,083 0 *
--------
* Represents less than 1% of our outstanding shares of common stock.
(1) All shares owned by the selling security holder reflect shares underlying
series C preferred stock (assuming the floor conversion rate of $1.55 per
share) except where indicated separately by footnote.
(2) The percentage of ownership of outstanding common stock in Columns (A) and
(B) above before and after the sale of shares registered hereunder is
based on the fully diluted number of shares of common stock outstanding
assuming the exercise of all warrants and options held by the selling
stockholder and registered hereunder, and taking into account conversion
of all of our series C convertible preferred stock at a conversion price
of $1.55 per share.
(3) The selling security holder is an employee of Dougherty & Company, LLC,
the placement agent in our private placement of series C preferred stock,
that has represented to us that he, she or it purchased the securities
registered in this registration statement in the ordinary course of
business and, at the time of purchase of those securities, had no
agreements or understandings, directly or indirectly, with any person to
distribute the securities.
19
(4) Includes 16,129 shares of common stock and warrants to purchase 12,887
shares of common stock held by the Richard and Louise Abrahams Charitable
Trust.
(5) Includes 16,129 shares of common stock and warrants to purchase 12,887
shares of common stock held by the Richard and Louise Abrahams Charitable
Trust and 41,936 shares of common stock and warrants to purchase 33,506
shares of common stock held by the RLA 1993 Trust.
(6) Voting control and investment power over the shares is held by Zesiger
Capital Group LLC, an investment advisory firm. Voting control and
investment power of Zesiger Capital Group LLC is exercised by or at the
direction of any of its managing members. The managing members of Zesiger
Capital Group LLC are Albert L. Zesiger, Barrie R. Zesiger, Lisa W. Hess,
James F. Cleary and John J. Kayola.**
(7) The selling security holder is a principal of Dougherty & Company, LLC,
the placement agent in the private placement of series C preferred stock.
The selling security holder purchased the securities registered in this
registration statement in the ordinary course of business and at the time
of purchase of those securities had no agreements or understandings,
directly or indirectly, with any person to distribute the securities.
(8) Voting control and investment power over the shares is held by Daniel
Asher.**
(9) Voting control and investment power over the shares is held by Daniel
Asher and Nathan Fischel.**
(10) Voting control and investment power over the shares is held by Stewart
Flink and Gary Elkins.**
(11) Voting control and investment power over the shares is held by Peter E.
Salas.**
(12) The selling security holder acted as the placement agent for our Series C
preferred stock private placement. Voting control and investment power
over the shares is held by Gerald Kraut.
(13) Voting control and investment power over the shares is held by Richard L.
Abrahams.**
(14) The selling security holder beneficially owns greater than 5% of our
common stock.
(15) The selling security holder holds the shares registered on this
registration statement in two entities under his common control -- Pine,
Inc. and Venturetec, Inc. BVI. Voting control and investment power over
these shares is held by Mr. Friedli.
(16) Includes:
. 196,472 shares of common stock held in the name of Pine, Inc. and
registered on this registration statement;
. 1,546,479 shares of common stock held in the name of Venturetec, Inc.
BVI and registered on this registration statement; and
. 373,521 shares of common stock held in the name of Venturetec and not
registered on this registration statement.
(17) Includes:
. warrants to purchase 87,148 shares of common stock held in the name of
Pine, Inc. and registered on this registration statement;
. warrants to purchase 9,320 shares of common stock held under the name
Pine, Inc. and not registered on this registration statement; and
. warrants to purchase 33,654 shares of common stock held in the name of
Venturetec, Inc. BVI and not registered on this registration statement.
(18) The selling security holder is a member of the immediate family of an
employee of Dougherty & Company, LLC.
(19) Voting control and investment power over the shares is held by Irvin R.
Kessler.**
(20) Voting control and investment power over the shares is held by James E.
Lineberger and James E. Lineberger, Jr.**
(21) Includes 16,129 shares of common stock and warrants to purchase 12,887
shares of common stock held by Bear Stearns as Custodian for Steven D.
McWhirter, IRA.
(22) Includes 16,129 shares of common stock and warrants to purchase 12,887
shares of common stock held by Bear Stearns as Custodian for Demetre M.
Nicoloff, IRA and 16,129 shares of common stock and warrants to purchase
12,887 shares of common stock held by Paine Weber as Custodian FBO
Demetre M. Nicoloff, IRA.
20
j(23) Voting control and investment power over the shares is held by Ira
Leventhal and Kevin Heneghan.**
(24) Voting control and investment power over the shares is held by Mark
Shoom.**
(25) The Peregine Fund, L.P. is controlled by Pepper Hamilton LLP, counsel to
the Company. Voting control and investment power over the shares is held
by a management committee comprised of James L. Murray, Barry M. Abelson,
Robert L. Hickok, Gilberto M. Villacorta and Michael B. Staebler.
** Based solely on information provided to us by the selling security holder
CARESIDE'S CAPITAL STRUCTURE
As of the effective date of this registration statement, we had 18,169,790
shares of common stock outstanding. The following table shows the eligibility
of these shares for public sale:
# of
Shares Eligibility for Public Resale
---------- -----------------------------
13,085,450 registered and freely tradable without restrictions or further
registration under the Securities Act
5,084,340 may be sold into the public market under Rule 144 currently,
without registration under the Securities Act
The following table shows the shares of common stock that we may issue in the
future and when we may issue them:
# of
Shares
Issuable
in the
Future When Issuable
---------- -------------
1,014,166 issuable upon exercise of outstanding options
2,000,000 issuable upon exercise of our publicly traded warrants
11,487,357 issuable upon exercise of outstanding warrants that are not
publicly traded
447,613 issuable upon exercise of options that we may grant under our
current stock option plans or pursuant to our employee stock
purchase plan
21
PLAN OF DISTRIBUTION
We are registering the common stock covered by this prospectus for selling
stockholders. As used in this prospectus, "selling stockholders" includes the
donees, pledgees, transferees or others who may later hold the selling
stockholders' shares of common stock registered herein. We will pay the costs,
expenses and fees in connection with registering the common stock, but the
selling stockholders will pay any brokerage commissions, discounts or other
expenses attributable to the sale of common stock.
The selling stockholders may sell the common stock from time to time in one
or more types of transactions (which may include block transactions), on the
American Stock Exchange, in negotiated transactions, through put or call option
transactions relating to the shares, through or a combination of such methods
of sale, at market prices prevailing at the time of sale, or at negotiated
prices. Such transactions may or may not involve brokers or dealers.
The selling stockholders may effect such transactions by selling shares
directly to purchasers or to or through broker-dealers, which may act as agents
or principals. Such broker-dealers may receive compensation in the form of
discounts, concessions, or commissions from the selling stockholders and/or the
purchasers of shares for whom such broker-dealers may act as agents or to whom
they sell as principal, or both (which compensation as to a particular broker-
dealer might be in excess of customary commissions).
The selling stockholders and any broker-dealers that act in connection with
the sale of shares might be deemed to be "underwriters" within the meaning of
Section 2(11) of the Securities Act, and any commissions received by such
broker-dealers and any profit on the resale of the shares sold by them while
acting as principals might be deemed to be underwriting discounts or
commissions under the Securities Act. The selling stockholders may agree to
indemnify any agent, dealer or broker-dealer that participates in transactions
involving sales of the shares against certain liabilities, including
liabilities arising under the Securities Act.
Because selling stockholders may be deemed to be "underwriters" within the
meaning of Section 2(11) of the Securities Act, the selling stockholders will
be subject to the prospectus delivery requirements of the Securities Act. We
have informed the selling stockholders that the anti-manipulative provisions of
Regulation M promulgated under the Exchange Act may apply to their sales in the
market.
Selling stockholders also may resell all or a portion of the shares in open
market transactions in reliance upon Rule 144 under the Securities Act,
provided they meet the criteria and conform to the requirements of such Rule.
If a selling stockholder notifies us that they have entered into or will
enter into any material arrangement with a broker or dealer for the sale of
shares of common stock through a block trade, special offering, exchange
distribution or secondary distribution or a purchase by a broker or dealer, a
supplement to this prospectus will be filed, if required, pursuant to Rule
424(b) under the Securities Act, as soon as practicable, but in no event later
than two business days after the arrangement has been entered into. This
supplement will disclose:
. the name of each such selling stockholder and of the participating
brokers or dealers;
. the number of shares of common stock involved;
. the price at which such shares were or will be sold;
. the commissions paid or to be paid or discounts or concessions allowed
or to be allowed to such brokers or dealers, where applicable;
22
. if applicable, that such brokers or dealers did not and will not conduct
any investigation to verify the information set out or incorporated by
reference in this prospectus; and
. other facts material to the transaction.
In addition, if a selling stockholder notifies us that a donee, pledgee or
other transferee intends to sell more than 500 shares of common stock, we will
file a supplement to this prospectus.
23
LEGAL MATTERS
The validity of the common stock offered hereby will be passed upon for us by
Pepper Hamilton LLP.
24
EXPERTS
The December 31, 2000 financial statements incorporated by reference in this
prospectus and elsewhere in the registration statement have been audited by
Arthur Andersen LLP, independent public accountants, as indicated in their
report with respect thereto, and are included herein in reliance upon the
authority of said firm as experts in giving said report. Reference is made to
said report, which includes an explanatory paragraph with respect to the
uncertainty regarding the Company's ability to continue as a going concern as
discussed in Note 1 to the financial statements.
25
WHERE YOU CAN GET MORE INFORMATION
Our fiscal year ends on December 31. We file annual, quarterly and current
reports, proxy statements and other information with the Securities and
Exchange Commission (the "Commission" or "SEC"). You may read and copy any
reports, statements or other information on file at the SEC's public reference
room in Washington, D.C. You can request copies of those documents, upon
payment of a duplicating fee, by writing to the SEC. Our SEC filings are also
available to the public at the SEC Internet site at http://www.sec.gov.
We have filed a registration statement on Form S-3 with the SEC. This
prospectus, which forms a part of the registration statement, does not contain
all of the information included in the registration statement. Certain
information is omitted. You should refer to the registration statement and its
exhibits. With respect to references made in this prospectus to any contract or
other document relating to us, such references are not necessarily complete.
You should refer to the exhibits attached to the registration statement for
copies of the actual contract or document. You may review a copy of the
registration statement at the SEC's public reference room in Washington, D.C.,
and at the SEC's regional offices in Chicago, Illinois and New York, New York.
Please call the SEC at 1-800-SEC-0330 for further information on the operation
of the public reference rooms. Our SEC filings, including the registration
statement, can also be reviewed by accessing the SEC's Internet site at
http://www.sec.gov.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by Careside with the Commission are
incorporated in this prospectus by reference:
. Careside's Annual Report on Form 10-K for the fiscal year ended December
31, 2000 filed on March 29, 2001 and Amendment No. 1 thereto on Form 10-
K/A filed on July 27, 2001 and Amendment No. 2 on Form 10-K/A filed on
September 12, 2001.
. Careside's Quarterly Report on Form 10-Q for the quarter ended March 31,
2001 filed on May 15, 2001 and Amendment No. 1 thereto on Form 10-Q/A
filed on July 27, 2001.
. Careside's Quarterly Report on Form 10-Q for the quarter ended June 30,
2001 filed on August 15, 2001.
. Careside's Registration Statement on Form 8-A filed on May 28, 1999
describing the terms, rights and provisions applicable to the common
stock, including any amendments or reports filed for the purpose of
updating such description.
. In addition, all documents subsequently filed by Careside pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the
termination of the offering shall be deemed to be incorporated by
reference herein from their respective dates of filing.
All financial statements included in the above-referenced filings should be
read in conjunction with the Risk Factors section of this prospectus.
Any statements contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained herein
or in any other subsequently filed document which also is incorporated or
deemed to be incorporated by reference herein modifies or supersedes such
statement. Any such statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this Prospectus.
26
You may also request a copy of these filings, at no cost, by writing or
telephoning James R. Koch at Careside at the following address:
Careside, Inc.
6100 Bristol Parkway
Culver City, California 90230
Telephone: (310) 338-6767
27
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
[CARESIDE LOGO]
14,195,890 Shares of Common Stock
----------------
PROSPECTUS
----------------
September 12, 2001
We have not authorized any dealer, salesperson or other person to give any
information or represent anything not contained in this prospectus. You must
not rely on any unauthorized information. This prospectus does not offer to
sell or buy any securities in any jurisdiction where it is unlawful. The
information in this prospectus is current as of its date.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth an itemization of all estimated expenses, in
connection with sale of the securities being registered payable by Careside:
Nature of Expense Amount
----------------- ----------
SEC Registration Fee........................................... $ 8,744.08
Printing and engraving fees.................................... $ 0
Registrant's counsel fees and expenses......................... $ 10,000
Accounting fees and expenses................................... $ 5,000
Miscellaneous.................................................. $ 5,000
----------
TOTAL........................................................ $28,744.08
Item 15. Indemnification of Directors and Officers.
Our Amended and Restated Certificate of Incorporation (the "Charter")
provides that we shall indemnify and advance expenses to the fullest extent
permitted by Section 145 of the Delaware General Corporation Law ("DGCL"), as
amended from time to time, to each person who is or was one of our directors or
officers and the heirs, executors and administrators of such a person. Any
expenses, including attorneys' fees, incurred by a person who is or was one of
our directors or officers, and the heirs, executors and administrators of such
a person in connection with defending any such proceeding in advance of its
final disposition shall be paid by us; provided, however, that if the DGCL
requires, an advancement of expenses incurred by an indemnitee in his capacity
as a director or officer, and not in any other capacity in which service was or
is rendered by such indemnitee, including, without limitation, service to an
employee benefit plan, such be made only upon delivery to us of an undertaking
by or on behalf of such indemnitee, to repay all amounts so advanced, if it
shall ultimately be determined that such indemnitee is not entitled to be
indemnified for such expenses. Notwithstanding the aforementioned
indemnification provisions, we may, at the discretion of our Chief Executive
Officer, enter into indemnification agreements with directors or officers.
Section 145 of the DGCL provides that a corporation has the power to
indemnify any director or officer, or former director or officer, who was or is
a party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative
or investigative, other than an action by or in the right of the corporation,
by reason of the fact that such director or officer or former director or
officer is or was a director, officer, employee or agent of the corporation,
against expenses, including attorneys' fees, judgments, fines and amounts paid
in settlement actually and reasonably incurred by them in connection with such
action, suit or proceeding, if such person shall have acted in good faith and
in a manner reasonably believed to be in or not opposed to the best interests
of the corporation, and, with respect to any criminal action or proceeding,
provided that such person had no reasonable cause to believe his or her conduct
was unlawful, except that, if such action shall be in the right of the
corporation, no such indemnification shall be provided as to any claim, issue
or matter as to which such person shall have been judged to have been liable to
the corporation unless and to the extent that the Court of Chancery of the
State of Delaware, or any court in which such suit or action was brought, shall
determine upon application that, in view of all of the circumstances of the
case, such person is fairly and reasonably entitled to indemnify for such
expenses as such court shall deem proper.
II-1
The Charter contains a provision to limit the personal liability of our
directors to the fullest extent permitted by Section 102(b)(7) of the DGCL, as
amended. In addition, the Amended and Restated By-Laws provide that we shall
indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether
civil, criminal, administrative or investigative, other than an action by us or
in our right, by reason of the fact that he is or was one of our directors,
officers, employees or agents, or is or was serving at our request as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses, including attorneys'
fees, judgments, fines and amounts paid in settlement actually and reasonably
incurred by him in connection with such action, suit or proceeding if he acted
in good faith and in a manner he reasonably believed to be in or not opposed to
our best interests, and, with respect to any criminal action or proceeding, had
no reasonable cause to believe his conduct was unlawful.
As permitted by the DGCL, the Charter provides that, subject to certain
limited exceptions, none of our directors shall be liable to us or our
stockholders for monetary damages for breach of fiduciary duty as a director,
except for liability (1) for any breach of the director's duty of loyalty to us
or our stockholders, (2) for acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law, (3) for the
unlawful payment of dividends on or redemption or repurchase of our capital
stock or (4) for any transaction from which the director derived an improper
personal benefit. The effect of this provision is to limit our ability and our
stockholders' ability through stockholder derivative suits on our behalf, to
recover monetary damages against a director for the breach of certain fiduciary
duties as a director, including breaches resulting from grossly negligent
conduct. In addition, the Charter and Amended and Restated By-Laws provide that
we shall, to the fullest extent permitted by the DGCL, indemnify all of our
directors and officers and that we may, to the extent permitted by the DGCL,
indemnify our employees and agents.
Item 16. Exhibits
Exhibit No. Description
----------- -----------
4.1 Certificate of Designations of Series C Convertible Preferred
Stock.*
4.2 Form of Securities Purchase and Subscription Agreement dated as of
March 29, 2001 by and between Careside, Inc. and Purchasers.*
4.3 Form of Warrant Agreement dated as of March 29, 2001 executed by
Careside, Inc. and addressed to Purchasers (including Warrant
Certificates).*
5.1 Opinion of Pepper Hamilton LLP
23.1 Consent of Arthur Andersen LLP
--------
* Incorporated herein by reference to Careside's Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 2001 filed on May 15, 2001 (SEC File
Number 001-15051).
Item 17. Undertakings.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant
has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
II-2
The undersigned registrant hereby undertakes:
To file during any period in which offers or sales are being made, a
post-effective amendment to this registration statement to:
To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933, as amended (the "Securities Act");
To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-
effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the dollar value of the
securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than a 20% change in the maximum
aggregate offering price set forth in the "Calculation of Registration
Fee" table in the effective registration statement, and
To include additional or changed material information on the plan of
distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.
That, for purposes of determining liability under the Securities Act,
each post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered, and the offering of the
securities at that time to be the initial bona fide offering thereof.
To remove from registration by means of a post-effective amendment any of
the securities being registered which remain unsold at the termination of
the offering.
That, for purposes of determining any liability under the Securities Act,
each filing of the registrant's annual report pursuant to Section 13(a) or
15(d) of the Securities Exchange Act of 1934 (and, where applicable, each
filing of an employee benefit plan's annual report pursuant to Section
15(d) of the Securities Exchange Act of 1934) that is incorporated by
reference in the registration statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.
In addition, the undersigned registrant hereby undertakes to provide to the
underwriters at the closing specified in the underwriting agreements,
certificates in such denominations and registered in such names as required by
the underwriters to permit prompt delivery to each purchaser.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the
registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-3 and has duly caused this
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized in Culver City, California, on this 12th day of September,
2001.
Careside, Inc.
/s/ W. Vickery Stoughton
By: _________________________________
W. Vickery Stoughton
Chairman of the Board of Directors
and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, as amended, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated:
Signature Title Date
--------- ----- ----
/s/ W. Vickery Stoughton Chairman of the Board of June 8, 2001
______________________________________ Directors, Chief
W. Vickery Stoughton Executive Officer and
Director (principal
executive officer)
/s/ Anthony P. Brenner Director June 8, 2001
______________________________________
Anthony P. Brenner
/s/ William F. Flatley Director June 9, 2001
______________________________________
William F. Flatley
/s/ S. Kenneth N. Kermes Director June 6, 2001
______________________________________
S. Kenneth N. Kermes
/s/ C. Alan MacDonald Director June 8, 2001
______________________________________
C. Alan MacDonald
/s/ Diana Mackie Director June 5, 2001
______________________________________
Diana Mackie
/s/ James R. Koch Executive Vice President, August 8, 2001
______________________________________ Chief Financial Officer,
James R. Koch Treasurer and principal
accounting officer
II-4